Did you know? You can suggest edits to improve this peptide information.
Overview
What is Orforglipron (Foundayo)?
Orforglipron (brand name Foundayo) is an FDA-approved oral, non-peptide GLP-1 receptor agonist and the first small-molecule GLP-1 approved for weight management. Approved April 2026 under the FDA's National Priority Voucher program, Foundayo can be taken once daily at any time without food or water restrictions. Clinical trials demonstrated up to 11.1% weight loss (24.9 lbs) at 72 weeks with the highest approved dose (17.2mg) and robust glycemic control (HbA1c reductions of 1.3-1.6%). Developed by Chugai Pharmaceutical and marketed by Eli Lilly. Available in 0.8mg, 2.5mg, 5.5mg, 9mg, 14.5mg, and 17.2mg tablets.
Key Benefits
FDA-approved for weight loss (up to 11.1% at 72 weeks), robust diabetes control (HbA1c reduction 1.3-1.6%), once-daily oral tablet taken any time of day, no refrigeration or food/water restrictions, reduced cardiovascular risk markers, available as low as $25/month with insurance
Mechanism of Action
Small-molecule GLP-1 receptor agonist with biased signaling - preferentially activates G protein/cAMP pathways (enhancing insulin secretion, suppressing glucagon, delaying gastric emptying, reducing appetite) while minimizing receptor desensitization. 79.1% oral bioavailability with 29-49 hour half-life supporting once-daily dosing.
Pharmacokinetics
Research Indications
Obesity Management Without Diabetes
FDA-approved based on ATTAIN-1 trial: 17.2mg dose achieved 11.1% weight loss (24.9 lbs) at 72 weeks in non-diabetic adults with obesity. 9mg achieved 8.3% (18.9 lbs), 5.5mg achieved 7.4% (17.2 lbs). First oral small-molecule GLP-1 approved for weight management.
Obesity Management With Type 2 Diabetes
ATTAIN-2 Phase 3 trial showed 9.6% weight loss (21.2 lbs) with 17.2mg in patients with both obesity and diabetes. 9mg achieved 7% (15.9 lbs), 5.5mg achieved 5.1% (11.7 lbs).
Cardiometabolic Risk Factor Improvement
Significant improvements in waist circumference, systolic blood pressure (8-12 mmHg reductions), triglycerides (-20-30%), and non-HDL cholesterol across Phase 3 trials. Comprehensive metabolic syndrome reversal.
Prediabetes Prevention
Among 1,127 ATTAIN-1 participants with prediabetes at baseline, up to 91% achieved near-normal blood sugar levels vs 42% with placebo, demonstrating diabetes prevention potential.
Research Protocols
Disclaimer
These are commonly discussed research protocols and not medical advice. Consult a healthcare provider before use.
Timing
Orforglipron can be taken at any time of day, with or without food or water. Choose a consistent time daily for optimal compliance. No fasting period or timing restrictions required.
Peptide Interactions
How to Take
Orforglipron is an oral tablet that requires no reconstitution or special preparation
Take one tablet once daily at the same time each day for consistency
Can be taken with or without food - no dietary restrictions required
Can be taken with or without water - no fasting period needed
Choose any convenient time of day (morning, afternoon, or evening)
Swallow tablet whole - do not crush, chew, or break unless directed by physician
If a dose is missed, take it as soon as remembered on the same day
If remembered on the next day, skip the missed dose and resume normal schedule
Never double dose to make up for a missed tablet
Store remaining tablets at room temperature (15-30°C) away from moisture and heat
No refrigeration required - stable at room temperature unlike injectable GLP-1 agonists
Keep in original packaging until ready to use to protect from light and moisture
Quality Indicators
Intact tablet packaging with proper labeling
Tablets should be in sealed blister packs or bottles with clear dosage labeling, batch numbers, and expiration dates. Packaging should show no signs of tampering.
Uniform tablet appearance and consistency
Tablets should have consistent color, shape, and size without discoloration, chipping, or cracking. Small molecule tablets should appear professionally manufactured.
Proper storage conditions maintained
Stored at room temperature (15-30°C) in dry environment away from direct sunlight, moisture, and heat. No refrigeration required unlike peptide GLP-1 agonists.
Valid prescription and legitimate pharmacy source
Product obtained through a licensed pharmacy, LillyDirect, or authorized telehealth provider with valid prescription. Look for official Foundayo branding and Eli Lilly packaging.
Discolored, crumbling, or damaged tablets
Tablets showing signs of degradation, unusual colors (yellowing, browning), brittleness, or physical damage indicate improper storage or expired product.
Moisture exposure or humidity damage
Tablets that feel soft, sticky, or show signs of moisture absorption. Package should protect from humidity. Damaged packaging compromises tablet stability.
Unverified or non-pharmacy sources
Only obtain Foundayo through licensed pharmacies, LillyDirect, or authorized telehealth providers. Products from unregulated online sources may be counterfeit or improperly stored.
Suspiciously low pricing or unregulated sources
Foundayo is available from $25/month with insurance or $149/month self-pay at the lowest dose. Products offered far below these prices from unregulated sources may be counterfeit or contaminated.
What to Expect
- •Appetite reduction typically within 1-3 days of first dose
- •Mild to moderate nausea common (usually improves significantly)
- •Diarrhea possible (19-26% of patients) - stay well hydrated
- •Gradual weight loss begins (0.5-2 lbs per week)
- •Improved blood sugar control within 1-4 weeks for diabetic patients
- •GI side effects generally diminish after first month
- •Reduced food cravings and enhanced satiety throughout the day
- •Energy levels normalize after initial adaptation period
- •Improved metabolic markers (blood pressure, lipids) become evident
- •Continued progressive weight loss without plateau
- •Peak weight loss effects typically seen at 36-72 weeks
- •Sustained improvements in cardiovascular risk factors
- •Long-term therapy well-tolerated in clinical trials
- •Participants show sustained benefits without plateau at 72 weeks
- •Ongoing diabetes prevention and metabolic health improvements
Side Effects & Safety
- BOXED WARNING: May cause thyroid C-cell tumors including medullary thyroid carcinoma (MTC). Contraindicated in patients with personal/family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Start at 0.8mg daily, titrate to 2.5mg after 30 days, then 5.5mg after 60 days - gradual titration minimizes GI side effects
- Do not use with other GLP-1 receptor agonist medicines
- Monitor for signs of acute pancreatitis (severe, persistent abdominal pain with or without nausea/vomiting) - stop taking Foundayo immediately if suspected
- Common side effects: nausea, constipation, diarrhea, vomiting, indigestion, abdominal pain, headache, bloating, fatigue, belching, heartburn, gas, and hair loss
- May cause dehydration leading to kidney problems - drink fluids to reduce risk, especially with nausea/vomiting/diarrhea
- May affect oral contraceptive efficacy - use alternative birth control for 30 days after starting and after each dose increase
- May require adjustment of insulin or sulfonylurea doses to prevent low blood sugar (hypoglycemia)
- Not safe during pregnancy (may harm unborn baby) or breastfeeding - pregnancy exposure registry available at 1-800-LillyRx
- Gallbladder problems reported - monitor for upper abdominal pain, fever, jaundice, or clay-colored stools
- Tell healthcare providers you take Foundayo before any surgery or procedure using anesthesia (aspiration risk)
- If doses missed for 7+ consecutive days, contact healthcare provider about how to restart treatment
References
ATTAIN-1 Phase 3 Trial (Obesity) - 2025
Highest approved dose (17.2mg) achieved 11.1% weight loss (24.9 lbs) vs 2.1% placebo. 9mg achieved 8.3% (18.9 lbs), 5.5mg achieved 7.4% (17.2 lbs). First oral small-molecule GLP-1 to complete Phase 3. Significant improvements in waist circumference, blood pressure, triglycerides, and non-HDL cholesterol.
ATTAIN-2 Phase 3 Trial (Obesity + T2DM) - 2025
Highest approved dose (17.2mg) achieved 9.6% weight loss (21.2 lbs). 9mg achieved 7% (15.9 lbs), 5.5mg achieved 5.1% (11.7 lbs). Demonstrated efficacy extends to patients with comorbid diabetes and obesity.
ACHIEVE-1 Phase 3 Trial (Type 2 Diabetes) - 2025
All doses significantly reduced HbA1c by 1.3-1.6% from 8.0% baseline vs 0.4% placebo. 76.2% achieved HbA1c <7%, 66.0% achieved ≤6.5%. 36mg dose produced 7.9% weight loss (16 lbs). First oral GLP-1 with no food/water restrictions to complete Phase 3.
Quick Start Guide
Community Poll
Question 1 of 10
What is your experience with this compound?
Poll Results
Loading results...
Community Insights
Self-reported by PepPedia users. Not clinical evidence. Health changes reflect all users, including those taking multiple compounds.
Was this helpful?
Your feedback helps us improve PepPedia